Baker Bros. Advisors LP Achilles Therapeutics PLC Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.75 - $1.25 $75,006 - $125,010	-100,008 Reduced 8.27%	1,108,767 $909,000
Q1 2024 May 15, 2024	SELL	$0.82 - $1.57 $733,093 - $1.4 Million	-894,017 Reduced 42.52%	1,208,775 $1.51 Million
Q4 2023 Feb 14, 2024	SELL	$0.78 - $0.96 $354,398 - $436,182	-454,357 Reduced 17.77%	2,102,792 $1.87 Million
Q2 2023 Aug 14, 2023	SELL	$0.82 - $1.09 $28,057 - $37,296	-34,217 Reduced 1.32%	2,557,149 $2.43 Million
Q1 2021 May 17, 2021	BUY	$16.55 - $16.55 $42.9 Million - $42.9 Million	2,591,366 New	2,591,366 $42.9 Million

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $43.6M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.